EMD Millipore, Precision Biologics in Process Development Pact

EMD Millipore has entered an agreement with Precision Biologics, Inc. to provide upstream process development services to advance a preclinical monoclonal antibody, NEO-201. The antibody binds to a tumor-specific antigen found in several forms of cancer, offering therapeutic potential across multiple cancer types, including colorectal, lung, ovarian, and pancreatic.

EMD Millipore will leverage its Provantage Service offering for biopharmaceutical manufacturing to help customers design and develop custom processes that improve yield and productivity. The company will work from its single-use GMP biodevelopment center in Martillac, France.

“We chose to partner with EMD Millipore because of their legacy of scientific and process development expertise,” said Philip M. Arlen, M.D., president and chief executive officer of Precision Biologics, Inc. “In addition to their experience in the development of processes for manufacturing monoclonal antibodies, their approach to the structure of our partnership was very appealing and well-suited to an emerging company like ours. We are confident that EMD Millipore will be a valuable partner in advancing NEO-201 and helping to bring a potential new therapeutic to patients in need.”

“We are delighted to partner with Precision Biologics, Inc. to support the process development for NEO-201 and its anticipated progression into clinical trials,” said Udit Batra, president and chief executive officer of EMD Millipore. “Our Provantage^®team is committed to developing an efficient, effective and robust manufacturing process to help reduce the time and cost required to advance this important pre-clinical drug candidate into the next phase for clinical production.”